http://purl.org/np/RAPXaK-EL6... RAPXaK-EL6

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#type type

http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement Statement

Leoni Bücken

2021-06-29T06:47:25.945Z

http://purl.org/np/RAPXaK-EL6... RAPXaK-EL6

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/2000/01/rdf-schema#label label

carefully consider the potential benefits and risks of indomethacin extended release capsules usp 75 mg and other treatment options before deciding to use indomethacin extended release capsules usp 75 mg use the lowest effective dose for the shortest duration consistent with individual patient treatment goals see warnings indomethacin extended release capsules usp 75 mg has been found effective in active stages of the following 1 moderate to severe rheumatoid arthritis including acute flares of chronic disease 2 moderate to severe ankylosing spondylitis 3 moderate to severe osteoarthritis 4 acute painful shoulder bursitis and or tendinitis indomethacin extended release capsules usp 75 mg are not recommended for the treatment of acute gouty arthritis indomethacin may enable the reduction of steroid dosage in patients receiving steroids for the more severe forms of rheumatoid arthritis in such instances the steroid dosage should be reduced slowly and the patients followed very closely for any possible adverse effects the use of indomethacin in conjunction with aspirin or other salicylates is not recommended controlled clinical studies have shown that the combined use of indomethacin and aspirin does not produce any greater therapeutic effect than the use of indomethacin alone furthermore in one of these clinical studies the incidence of gastrointestinal side effects was significantly increased with combined therapy see precautions drug interactions

Leoni Bücken

2021-06-29T06:47:25.945Z

http://purl.org/np/RAPXaK-EL6... RAPXaK-EL6

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#object object

http://purl.obolibrary.org/obo/DOID_971 DOID_971

Leoni Bücken

2021-06-29T06:47:25.945Z

http://purl.org/np/RAPXaK-EL6... RAPXaK-EL6

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate predicate

https://w3id.org/biolink/vocab/treats treats

Leoni Bücken

2021-06-29T06:47:25.945Z

http://purl.org/np/RAPXaK-EL6... RAPXaK-EL6

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#subject subject

https://identifiers.org/drugbank:DB00328 drugbank:DB00328

Leoni Bücken

2021-06-29T06:47:25.945Z

http://purl.org/np/RAPXaK-EL6... RAPXaK-EL6

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/association_type association_type

https://w3id.org/biolink/vocab...OrPhenotypicFeatureAssociation ChemicalToDiseaseOrPhenotypicFeatureAssociation

Leoni Bücken

2021-06-29T06:47:25.945Z

http://purl.org/np/RAPXaK-EL6... RAPXaK-EL6

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/provided_by provided_by

https://w3id.org/um/NeuroDKG NeuroDKG

Leoni Bücken

2021-06-29T06:47:25.945Z

http://purl.org/np/RAPXaK-EL6... RAPXaK-EL6

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/relation relation

https://schema.org/TreatmentIndication TreatmentIndication

Leoni Bücken

2021-06-29T06:47:25.945Z